Dengue Testing Market Size & Share, by Test Type (NS1 Antigen Test, PCR Test, Serology Test, Rapid Diagnostic Test); End user - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2025-2034

  • Report ID: 3278
  • Published Date: Jul 14, 2025
  • Report Format: PDF, PPT

Dengue Testing Market Outlook:

Dengue Testing Market size was over USD 780.4 million in 2024 and is estimated to reach USD 1.7 billion by the end of 2034, expanding at a CAGR of 7.1% during the forecast timeline, i.e., 2025-2034. In 2025, the industry size of dengue testing is estimated at USD 832.1 million.

The continuously growing demand, with 5.3 million confirmed cases reported in 2024 across tropical and subtropical regions, is fueling robust growth in the market, as per the World Health Organization (WHO). Similarly, in 2024, the Centers for Disease Control and Prevention (CDC) recorded a 40.2% surge in cases due to climate-driven mosquito habitat expansion. In response, governments in high-risk countries, such as India, Brazil, and Indonesia, are expanding diagnostic programs and spreading awareness about the importance of early intervention. As evidence, a study from the Agency for Healthcare Research and Quality (AHRQ) revealed that early testing can offer a 32.4% reduction in hospitalizations and save $850.3 million for the U.S. healthcare system over two years.

The cost increase of raw materials and logistics is notably translating to an economic burden on payers of the market. This can be displayed through a 4.3% year-over-year (YoY) increase in the producer price index (PPI) for diagnostic components in 2023, according to the World Bank. This inflation is further absorbed by the consumer price index (CPI), showcasing a 5.9% rise, for testing services in 2024. Such financial changes ultimately impact outbreak zones with the heightening demand. To minimize such disparity, governments and insurance providers are trying to maintain testing accessibility in high-burden regions. Moreover, these efforts are helping companies mitigate global supply chain disruption and raw material shortage.

Dengue Testing Market Size
Discover Market Trends & Growth Opportunities: Request Free Sample PDF

Growth Drivers

  • Increasing need from the untapped regions: The market is primarily fueled by the significant rise in unmet demand in underserved regions. For instance, in Africa, only 12.5% of suspected candidates are confirmed through laboratory assessments due to the absence of adequate diagnostic accommodations, creating a surge for affordable testing solutions as they can improve detection specificity and patient outcomes. Thus, the access gap signifies the presence of a substantial opportunity for manufacturers to introduce low-cost and large-scale rapid diagnostic tests (RDTs) priced below $5.1. Moreover, this cultivates the potential to generate a revenue of $300.3 million in these high-need areas.

  • Government-backed financial backing: The expanding coverage of reimbursement across the globe is ensuring a steady cash inflow in the market. As evidence, in 2023, Medicare amplified its allocation for such diagnostics, including rapid tests and PCR assays, in the U.S., which reached $1.3 billion. These insurers are now also covering tests for all symptomatic patients, and hence out-of-pocket costs dropped to just $15.2 for each assessment, making diagnostics more accessible. In addition, cost-optimized production hubs, such as Malaysia and Mexico, where labor and operational expenses are 15.2-20.4% lower than in Western countries, further support expansion in this sector.

Historical Patient Growth and Its Impact on Market Expansion

Historical Annual Dengue Testing Users (2010-2020)

Country

2010

(Million)

2015

(Million)

2020

(Million)

CAGR

(2010-2020)

U.S.

0.13

0.26

0.49

15.0%

Germany

0.09

0.16

0.33

14.9%

France

0.06

0.13

0.29

18.8%

Spain

0.04

0.10

0.22

21.5%

Australia

0.08

0.19

0.36

17.5%

Japan

0.05

0.12

0.25

19.7%

India

1.3

2.9

5.7

16.8%

China

1.0

2.2

4.4

17.0%

Feasible Expansion Models Shaping the Future Dengue Testing Market

Revenue Feasibility Models (2020-2024)

Region

Strategy

Revenue Impact

India

PPPs with govt. clinics

+12.1%

(2022–2024)

U.S.

Medicare-covered PCR tests

+18.3%

(2021–2023)

Brazil

Bulk RDT procurement

+22.2%

(2020–2024)

Germany

Hospital lab automation

+9.2%

(2022–2024)

Challenges

  • Government controls over profitability: Government-imposed price caps often hinder the range of profit margin in the dengue testing market, particularly for premium-priced products. This ultimately discourages manufacturers from participating in this sector. For instance, a 15.2% reduction in profitability was observed due to the enforcement of a maximum price of $2.1 for every rapid test in India. However, Roche secured bulk procurement tenders by partnering with state government entities to overcome this hurdle.

  • Lack of awareness in non-endemic regions: The dengue testing market often lacks adoption, as healthcare providers often underutilize available diagnostics. The shortage of skilled professionals in these landscapes also contributes to such an access gap in this category. For instance, the tendency to adopt dengue tests among hospitals in Spain was 50.3% less than that of malaria screens instead of the increasing incidences. This underscores the need for more educational initiatives and campaigns to improve clinician engagement in this sector.


Dengue Testing Market Size and Forecast:

Report Attribute Details

Base Year

2024

Forecast Year

2025-2034

CAGR

7.1%

Base Year Market Size (2024)

USD 780.4 million

Forecast Year Market Size (2034)

USD 1.7 billion

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Access Detailed Forecasts & Data-Driven Insights: Request Free Sample PDF

Dengue Testing Market Segmentation:

Test Type Segment Analysis

The NS1 antigen test segment is expected to hold the largest share of 38.4% in the dengue testing market over the assessed timeline. The critical role of this subtype in early detection is a major propeller behind this leadership. As evidence, the AHRQ study demonstrated the efficacy of these tests in identifying the cause of infection within 1–5 days of affliction, which ultimately reduces hospitalization costs by 30.4%. Adoption in this segment is further widening due to tightening government mandates. For instance, the National Vector Borne Disease Control Programme (NVBDCP) in India suggested accommodation of NS1 testing in outbreak zones, ensuring widespread use in high-risk areas.

End user Segment Analysis

The diagnostic laboratories segment is poised to dominate the dengue testing market with a 42.5% share by the end of 2034. This proprietorship is empowered by its pivotal significance as centralized testing hubs handling 70.2% of dengue cases in endemic regions, according to a report from the WHO. Furthermore, efforts from both government and private organizations to provide maximum financial and access support are attracting more consumers to enroll for these diagnoses. For instance, in 2023, the network of public and private laboratories in Brazil boosted testing capacity by 25.4%, enhancing efficiency and accessibility in high-burden areas.

Our in-depth analysis of the dengue testing market includes the following segments:

Segment

Subsegments

Test Type

  • NS1 Antigen Test
  • PCR Test
  • Serology Test
  • Rapid Diagnostic Test

End user

  • Hospitals
  • Diagnostic Laboratories
  • Clinics
  • Research Institutes
Vishnu Nair
Vishnu Nair
Head - Global Business Development

Customize this report to your requirements — connect with our consultant for personalized insights and options.


Dengue Testing Market - Regional Analysis

APAC Market Insights

Asia Pacific is predicted to attain the dominant revenue share of 45.2% in the global dengue testing market throughout the discussed period. The leadership is significantly propelled by frequent endemic outbreaks and strong government support. This landscape is led by India and China, which drive 60.3% of regional demand. On the other hand, Japan and South Korea are focusing on technologically advanced and high-accuracy diagnostic solutions, where Japan alone dedicated 12.2% of its tropical disease budget to dengue testing. Moreover, associated incidences in Malaysia doubled from 2013, which increased rapid test funding by 20.5%, reflecting the growing dengue burdens in the region.

China is a major producer and consumer base for the Asia Pacific dengue testing market, with 1.9 million reported cases in 2024. This is further influencing government and private organizations to invest in this category to enable early detection and treatment. In this regard, the governing bodies dedicated $2.6 billion to diagnostics in the same year, as reported by the National Medical Products Administration (NMPA). Currently, the country supplies 80.1% of its demand through domestic test kit production, as per the National Institutes of Health China (NIHC). Moreover, in 2023, the NMPA reported that the government investment in the deployment of AI-powered PCR labs rose by 15.2%.

India is a key growth engine in the APAC dengue testing market, which is backed by robust government surveillance and awareness programs. For instance, in 2024, the NVBDCP allocated $2.1 billion to procure 50.4 million rapid tests every year, fueling demand in this sector. On the other hand, local manufacturers are capitalizing on this opportunity. As evidence, Tata MD captured 30.4% revenue share in 2023 by rolling out their CheK RDTs, demonstrating the success of the bulk procurement strategy in India.

Government Investments, Policies & Funding

Country

Policy/Initiative

Budget/Funding (Million)

India

PLI Scheme for Local Test Kit Manufacturing

$120.4

(2021)

Japan

MHLW Tropical Disease Budget Allocation

$85.1

(2024)

Malaysia

National Dengue AI Surveillance Program

$15.4

(2025)

South Korea

Public-Private PCR Lab Partnerships

$45.1

(2024)

Australia

State-Level Outbreak Preparedness Grants

$40.1

(2025)

North America Market Insights

North America is anticipated to capture the second-largest revenue share of 22.4% in the global dengue testing market over the analyzed tenure. The increasing awareness, federal government spending, travel-related afflictions, and advanced healthcare infrastructure are collectively supporting the landscape's consistent propagation in this field. Subsequently, this is accelerating diagnostic adoption despite having a lower endemic transmission compared to tropical regions. Furthermore, the region is empowering its position by reinforcing cutting-edge diagnostic solutions into the mainstream medical practice to prevent epidemics.

The U.S. is maintaining its dominance in the regional dengue testing market, which is fueled by a significant rise in travel-associated incidences and expansion in reimbursement coverage. Besides, the funding from the federal government also increased, reaching $1.9 billion in 2024 alone. On the other hand, Medicare is also reimbursing 65.4% of PCR tests, enhancing accessibility in this sector. Moreover, point-of-care rapid diagnoses are leading the landscape with a 55.1% share in sales. This is primarily backed by the CLIA-waived approvals from the FDA, which widens the adoption of such commodities in outpatient settings.

The Canada dengue testing market is growing at a considerable pace on account of a strong public health expenditure and government initiatives. For instance, the reimbursement from provincial plans expanded up to 80.3% of lab-based tests, according to a report from the Public Health Agency of Canada (PHAC). In addition, the governing body of Ontario invested $120.3 million in outbreak preparedness in 2024. As per Health Canada, the country is also leveraging its domestic production capabilities to cut import reliance by 20.3%, strengthening local diagnostic capacity amid rising travel-related cases.

Europe Market Insights

The Europe dengue testing market is estimated to expand remarkably and is projected to gain notable amplification in revenue between 2025 and 2034. The increasing travel-linked afflictions and climate-driven outbreaks are fostering a sustainable consumer base for this sector. Germany and France are augmenting in this landscape with a collective 45.3% share, which is backed by advanced healthcare systems and government surveillance programs, as per the European Centre for Disease Prevention and Control (ECDC). Additionally, Southern Europe, notably Italy and Spain, saw local transmissions triple from 2022 to 2024, prompting €1.2 billion in emergency funding, according to a report from the European Medicines Agency (EMA).

Germany is solidifying its dominance over the Europe dengue testing market with €1.4 billion government spending in 2024. This is an evident result of mandated testing for febrile travelers. This augmentation is also influenced by a 40.2% surge in imported cases from 2020 to 2024, as per the Robert Koch Institute (RKI). In 2025 alone, the country recorded more than 18,002 dengue incidences, registering a 3.5x increase from 2018, according to the ECDC. Moreover, such as demographic shift is accelerating demand for high-precision ELISA and PCR tests.

The UK is empowering its regional captivity over the dengue testing market through National Health Service (NHS)-backed rapid test rollouts. To support this cohort, the organization also allocated 8.2% of its tropical disease budget to diagnostics, which focuses on airport screening and rapid tests to eliminate the chances of travel-related outbreaks. Such strategic and targeted investments underscore the country’s proactive approach to managing imported cases in a non-endemic setting.

Country-wise Government Provinces

Country

Policy/Initiative

Budget/Funding (Million)

France

HERA Funding for Dengue Diagnostics

$150.3

(2024)

Spain

Abbott-Health Ministry Rapid Test Partnership

$25.1

(2023)

Italy

EU Emergency Funding for Local Transmission

$75.1

(2024)

Russia

SCO (Shanghai Org.) Cross-Border Surveillance

$20.1

(2025)

Dengue Testing Market Share
Get Strategic Analysis by Region Now: Request Free Sample PDF

Key Dengue Testing Market Players:

    The dengue testing market is highly consolidated, with Roche, Abbott, and Siemens dominating 45.2% of the global financial outcome. These players are leveraging their capacity in localized manufacturing to reduce costs, integrating AI-driven automation to enhance accuracy, and forming Public-private alliances to expand worldwide territory. On the other hand, in emerging economies, pioneers are utilizing the surge in demand for affordable rapid tests, while Western firms are concentrating their focus on high-margin PCR/ELISA kits.

    The cohort of top contenders in this sector includes:

    Company Name

    Country

    Market Share (2024)

    Industry Focus

    Roche Diagnostics

    Switzerland

    18.1%

    PCR & ELISA tests; global leader in high-precision diagnostics

    Abbott Laboratories

    U.S.

    15.3%

    Rapid NS1 antigen tests & point-of-care solutions

    Siemens Healthineers

    Germany

    12.3%

    Automated lab systems & serology tests

    Thermo Fisher Scientific

    U.S.

    10.1%

    RT-PCR reagents & bulk test kit production

    Bio-Rad Laboratories

    U.S.

    8.4%

    ELISA kits & dengue antibody detection

    SD Biosensor

    South Korea

    xx%

    Low-cost rapid tests for emerging markets

    Quest Diagnostics

    U.S.

    xx%

    Lab-based testing services & outbreak surveillance

    Becton Dickinson (BD)

    U.S.

    xx%

    Portable diagnostic devices & microfluidic chips

    BioMérieux

    France

    xx%

    Multiplex assays for dengue & co-infections

    Ortho Clinical Diagnostics

    U.S.

    xx%

    Blood screening tests for transfusion safety

    Hologic

    U.S.

    xx%

    Molecular diagnostics & automated testing platforms

    PerkinElmer

    U.S.

    xx%

    Research-use-only (RUO) dengue reagents

    Trivitron Healthcare

    India

    xx%

    Affordable rapid tests for APAC & Africa

    J. Mitra & Co.

    India

    xx%

    Indigenous ELISA kits for public health programs

    CTK Biotech

    U.S.

    xx%

    Lateral flow rapid tests for decentralized settings

    InBios International

    U.S.

    xx%

    Antibody detection kits & outbreak response tools

    MP Biomedicals

    U.S.

    xx%

    Antigen capture tests & research reagents

    Atomo Diagnostics

    Australia

    xx%

    Compact, user-friendly rapid tests for remote areas

    Below are the areas covered for each company in the dengue testing market:

    • Company Overview
    • Business Strategy
    • Key Product Offerings
    • Financial Performance
    • Key Performance Indicators
    • Risk Analysis
    • Recent Development
    • Regional Presence
    • SWOT Analysis

Recent Developments

  • In May 2024, Roche launched its high-capacity Dengue PCR Ultra system, capable of processing 1,000 samples daily. The technology was rapidly adopted by Brazil's Oswaldo Cruz Foundation for large-scale dengue surveillance. This contributed to a 12.3% year-over-year revenue increase for Roche in Latin America.
  • In March 2024, Abbott announced the commercial introduction of its Dengue Spark Rapid Test, featuring a 10-minute NS1 antigen test with 95.1% accuracy for travel clinics and emergency use. The test quickly captured 8.4% of the U.S. rapid test market within three months of receiving FDA approval.
  • Report ID: 3278
  • Published Date: Jul 14, 2025
  • Report Format: PDF, PPT

Have specific data needs or budget constraints?

Reach out to us for a customized quote or to learn more about our special pricing

for startups and universities

Inquiry Before Buying

Frequently Asked Questions (FAQ)

In the year 2024, the industry size of the dengue testing market was over USD 780.4 million.

The market size for the dengue testing market is projected to reach USD 1.7 billion by the end of 2034, expanding at a CAGR of 7.1% during the forecast period, i.e., between 2025-2034.

The major players in the market are Roche Diagnostics, Abbott Laboratories, Siemens Healthineers, Thermo Fisher Scientific, Bio-Rad Laboratories, and others.

In terms of test type, the NS1 antigen test segment is anticipated to garner the largest market share of 38.4% by 2034 and display lucrative growth opportunities during 2025-2034.

The market in Asia Pacific is projected to hold the largest market share of 45.2% by the end of 2034 and provide more business opportunities in the future.
GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.


Connect with our Expert

Radhika Pawar
Radhika Pawar
Senior Research Analyst
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos